Zellin G, Linde A
Department of Oral Biochemistry, Göteborg University, Sweden.
Plast Reconstr Surg. 1999 Apr;103(4):1229-37. doi: 10.1097/00006534-199904040-00019.
For bone reconstructive purposes, it would be a great advantage to be able to gain bone without grafting. In experimental studies, barrier membranes have been used to accomplish this, however, with limited efficacy. In this study, the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the early onset of bone formation, as well as on the final amount of achievable bone, was investigated in an experimental osteo-neogenesis model. In 60 adult rats, dome-shaped barrier membranes made of expanded polytetrafluoroethylene (Gore-Tex membrane), with an inside volume of approximately 60 mm3, were placed on the left parietal bone. The domes were pretreated according to four different alternatives: (1) filled with autogenous blood only (n = 15); (2) filled with 5 microg of rhBMP-2 in an absorbable collagen sponge carrier (n = 15); (3) filled with 15 microg of rhBMP-2 in absorbable collagen sponge carrier (n = 15); or (4) filled with the absorbable collagen sponge carrier only (n = 15). The animals treated according to each alternative were then divided into three equal groups with five rats in each, and subsequently killed after 3, 6, or 12 weeks. The amount of bone formed within the domes was evaluated by light microscopy and computer-assisted image analysis. It was found that the amount of newly formed bone could be enhanced by approximately 100 percent by simultaneous implantation of rhBMP-2, irrespective of dose. The early onset of bone formation was, however, not affected by the rhBMP-2 supplementation. This finding was interpreted as being due to the delivery system used, because as long as the carrier was still present, no significant difference between the treatment groups was observed. The bone formed in domes with carrier implantation, with or without rhBMP-2, displayed more marrow spaces in comparison to controls. The combined treatment with barrier membranes and local delivery of rhBMP-2 may be a useful tool in reconstructive surgery, for instance replacing onlay grafting, especially when a more delicate anatomy is necessary, because membranes can be shaped in multiple ways.
为了实现骨重建,若能在不进行骨移植的情况下获得骨组织将具有极大优势。在实验研究中,曾使用屏障膜来达成这一目标,然而,其效果有限。在本研究中,我们在一个实验性骨生成模型中,研究了重组人骨形态发生蛋白-2(rhBMP-2)对骨形成早期起始以及最终可获得骨量的影响。在60只成年大鼠的左顶骨上放置由膨体聚四氟乙烯制成的圆顶形屏障膜(戈尔特斯膜),其内部容积约为60立方毫米。根据四种不同方案对圆顶进行预处理:(1)仅填充自体血(n = 15);(2)在可吸收胶原海绵载体中填充5微克rhBMP-2(n = 15);(3)在可吸收胶原海绵载体中填充15微克rhBMP-2(n = 15);或(4)仅填充可吸收胶原海绵载体(n = 15)。然后,将按照每种方案处理的动物平均分为三组,每组五只,并在3周、6周或12周后处死。通过光学显微镜和计算机辅助图像分析评估圆顶内形成的骨量。结果发现,无论剂量如何,同时植入rhBMP-2可使新形成的骨量增加约100%。然而,rhBMP-2补充剂并未影响骨形成的早期起始。这一发现被解释为是由于所使用的递送系统,因为只要载体仍然存在,各治疗组之间未观察到显著差异。与对照组相比,植入载体(无论有无rhBMP-2)的圆顶内形成的骨显示出更多的骨髓腔隙。屏障膜与rhBMP-2局部递送的联合治疗可能是重建手术中的一种有用工具,例如替代覆盖植骨,特别是在需要更精细解剖结构时,因为膜可以多种方式塑形。